Thyroid Gland Papillary Carcinoma

In summary, we report 7 new BRAF fusions in PTC BRAF V600E-WT. Additional clinical research is needed to elucidate the behavior of BRAF fusion-driven thyroid carcinomas and the therapeutic utility of MAPK pathway inhibitors.

BA treatment upregulates PLAU gene expression, but this increased PLAU protein subsequently interacts with and inhibited by BA, leading to downstream pathway suppression. It was concluded it could be served as a promising therapeutic strategy for the treatment of PTC.

Integrating transcriptomic data into clinical decision-making enables more precise selection for treatment escalation or de-escalation. To unlock the full potential of transcriptome-guided management in PTC, prospective validation and adoption into ATA and NCCN guidelines will be critical.

Despite the frequency of lymphatic metastasis, its prognostic impact varies: microscopic nodal disease has minimal effect on survival, while macroscopic or extranodal extension increases recurrence and mortality risks. This synthesis of current evidence aims to guide clinicians in optimizing detection, treatment, and surveillance for PTC patients with lymphatic metastasis.

Multivariate analysis demonstrated that increasing age (odds ratio (OR), 1.07; 95% confidence interval (CI), 1.01-1.13; p = 0.015), tumor size (OR, 1.86; 95% CI, 1.12-3.08; p = 0.016), and lymph node metastasis (OR, 3.50; 95% CI, 1.09-6.53; p = 0.026) were independently associated with pTERT mutations. ddPCR enables sensitive detection of pTERT mutations in archived FFPE thyroid cancer specimens and identifies tumors with aggressive clinicopathological features, supporting its utility for postoperative risk stratification in clinical practice.

The presence of CLT appears to exert a protective effect in PTC. However, the prognostic significance of BRAF V600E mutation varies with tumor size. While CLT-related inflammatory microenvironment may counteract tumor progression in small cancers, it seems insufficient to mitigate the aggressive behavior driven by BRAF V600E mutation in larger tumors.

P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting

In young patients with ITN, the Afirma GSC demonstrated an excellent negative predictive value when defining a TN result by histology or clinical follow-up.

Preoperative NGS profiling, particularly the detection of high-risk multi-gene co-mutations, provides a powerful tool for refined risk assessment. This molecularly guided strategy has the potential to inform personalized surgical planning directly, optimizing the extent of lymph node dissection to improve oncologic outcomes while minimizing unnecessary morbidity.

Preliminary results indicate that the biomarker panel combining serum miR-485-3p levels with CDUS parameters shows diagnostic potential for PTC. In vitro experiments confirmed the potential of the miR-485-3p/GCNT4 axis in modulating the malignant behavior of PTC cells.

Furthermore, the preclinical investigation demonstrated that targeting this newly identified signaling with lipofermata (a FATP2-specific inhibitor) suppressed PTC progression. Together, these findings suggest that adipocytes in the PTC microenvironment may function via FATP2/TR4 signaling to regulate PTC progression, and targeting this newly identified adipocyte/FATP2/TR4 signaling axis may facilitate the development of novel therapeutic strategies for PTC.

P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2028 --> Feb 2029